Castejon Ana Maria, Spaw Jordan Ashley, Rozenfeld Irina, Sheinberg Nurit, Kabot Susan, Shaw Alexander, Hardigan Patrick, Faillace Rogerio, Packer Edward E
Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL, United States.
Center for Collaborative Research, Institute for Neuro Immune Medicine, Nova Southeastern University, Fort Lauderdale, FL, United States.
Front Psychiatry. 2021 Sep 30;12:669089. doi: 10.3389/fpsyt.2021.669089. eCollection 2021.
Previous studies indicate that children with autism spectrum disorder (ASD) have lower levels of glutathione. Nutritional interventions aim to increase glutathione levels suggest a positive effect on ASD behaviors, but findings are mixed or non-significant. A commercially available nutritional supplement comprising a cysteine-rich whey protein isolate (CRWP), a potent precursor of glutathione, was previously found to be safe and effective at raising glutathione in several conditions associated with low antioxidant capacity. Therefore, we investigated the effectiveness of a 90-day CRWP intervention in children with ASD and examined whether intracellular reduced and oxidized glutathione improvements correlated with behavioral changes. We enrolled 46 (of 81 screened) 3-5-year-old preschool children with confirmed ASD. Using a double-blind, randomized, placebo-controlled design, we evaluated the effectiveness of daily CRWP (powder form: 0.5 g/kg for children <20 kg or a 10-g dose for those >20 kg), compared with placebo (rice protein mimicking the protein load in the intervention group), on glutathione levels and ASD behaviors assessed using different behavioral scales such as Childhood Autism Rated Scale, Preschool Language Scale, Social Communication Questionnaire, Childhood Behavioral Checklist and the parent-rated Vineland Adaptive Behavior Scale, 2nd edition (VABS-II). Forty children (CRWP, 21; placebo, 19) completed the 90-day treatment period. Improvements observed in some behavioral scales were comparable. However, the VABS-II behavioral assessment, demonstrated significant changes only in children receiving CRWP compared to those observed in the placebo group in the composite score (effect size 0.98; 95% confidence intervals 1.42-4.02; = 0.03). Further, several VABS-II domain scores such as adaptive behavior ( = 0.03), socialization ( = 0.03), maladaptive behavior ( = 0.04) and internalizing behavior ( = 0.02) also indicated significant changes. Children assigned to the CRWP group showed significant increases in glutathione levels ( = 0.04) compared to those in the placebo group. A subanalysis of the VABS-II scale results comparing responders (>1 SD change from baseline to follow up) and non-responders in the CRWP group identified older age and higher levels of total and reduced glutathione as factors associated with a response. CRWP nutritional intervention in children with ASD significantly improved both glutathione levels and some behaviors associated with ASD. Further studies are needed to confirm these results. https://clinicaltrials.gov/ct2/show/study/NCT01366859, identifier: NCT01366859.
先前的研究表明,患有自闭症谱系障碍(ASD)的儿童体内谷胱甘肽水平较低。旨在提高谷胱甘肽水平的营养干预措施显示对ASD行为有积极影响,但研究结果不一或无显著意义。先前发现,一种市售营养补充剂,其包含富含半胱氨酸的乳清蛋白分离物(CRWP),谷胱甘肽的一种有效前体,在几种与抗氧化能力低相关的情况下,能安全有效地提高谷胱甘肽水平。因此,我们调查了为期90天的CRWP干预对ASD儿童的有效性,并检查细胞内还原型和氧化型谷胱甘肽的改善是否与行为变化相关。我们招募了46名(在81名筛查对象中)确诊为ASD的3至5岁学龄前儿童。采用双盲、随机、安慰剂对照设计,我们评估了每日CRWP(粉末形式:体重<20 kg的儿童为0.5 g/kg,体重>20 kg的儿童为10 g剂量)与安慰剂(模仿干预组蛋白质含量的大米蛋白)相比,对使用不同行为量表评估的谷胱甘肽水平和ASD行为的有效性,这些量表包括儿童自闭症评定量表、学前语言量表、社会交往问卷、儿童行为清单以及家长评定的第二版文兰适应行为量表(VABS-II)。40名儿童(CRWP组21名;安慰剂组19名)完成了为期90天的治疗期。在一些行为量表上观察到的改善相当。然而,VABS-II行为评估显示,与安慰剂组相比,仅接受CRWP的儿童在综合得分上有显著变化(效应大小0.98;95%置信区间1.42 - 4.02;P = 0.03)。此外,VABS-II的几个领域得分,如适应行为(P = 0.03)、社交(P = 0.03)、适应不良行为(P = 0.04)和内化行为(P = 0.02)也显示有显著变化。与安慰剂组相比,分配到CRWP组的儿童谷胱甘肽水平显著升高(P = 0.04)。对CRWP组中反应者(从基线到随访变化>1个标准差)和无反应者的VABS-II量表结果进行的亚分析确定,年龄较大以及总谷胱甘肽和还原型谷胱甘肽水平较高是与反应相关的因素。对ASD儿童进行CRWP营养干预可显著提高谷胱甘肽水平以及一些与ASD相关的行为。需要进一步研究来证实这些结果。https://clinicaltrials.gov/ct2/show/study/NCT01366859,标识符:NCT01366859